Literature DB >> 23865457

Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.

I Ljungvall1, K Höglund, I Lilliehöök, M A Oyama, A Tidholm, H Tvedten, J Häggström.   

Abstract

BACKGROUND: The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has recently been suggested to play a role in the development of naturally acquired myxomatous mitral valve disease (MMVD) in dogs. AIM: To investigate the association between serum 5-HT concentration and MMVD severity in dogs, and to assess potential associations between serum 5-HT concentrations and dog characteristics, echocardiographic variables, heart rate, systolic blood pressure, presence of macrothrombocytosis, and plateletcrit. ANIMALS: A total of 120 client-owned dogs.
MATERIAL AND METHODS: Dogs were prospectively recruited and were classified by standard echocardiography into healthy (dogs of breeds predisposed to MMVD, but without echocardiographic evidence of the disease), mild, moderate, or severe MMVD groups. Serum 5-HT concentrations were analyzed using an ELISA.
RESULTS: Dogs with severe MMVD had lower serum 5-HT concentrations than healthy dogs (P = .0025) and dogs with mild MMVD (P = .0011). Unilinear and multiple regression analyses showed that serum 5-HT concentrations decreased with increasing left atrial to aortic root ratio (LA/Ao), were higher in Cavalier King Charles Spaniel (CKCS) dogs compared to dogs of other breeds, and were higher in female dogs than in male dogs. The LA/Ao was the variable most strongly associated with serum 5-HT concentration. CONCLUSIONS AND CLINICAL IMPORTANCE: The finding of higher serum 5-HT concentrations in dogs of breeds predisposed to the early onset of MMVD (CKCS) and dogs with mild MMVD suggests that alterations in 5-HT signaling might play a role in progression of early stages of MMVD.
Copyright © 2013 by the American College of Veterinary Internal Medicine.

Entities:  

Keywords:  Canine myxomatous disease; Cardiology; Platelet function; Valvular disease

Mesh:

Substances:

Year:  2013        PMID: 23865457     DOI: 10.1111/jvim.12137

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  12 in total

Review 1.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

2.  Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.

Authors:  S E Cremer; G E Singletary; L H Olsen; K Wallace; J Häggström; I Ljungvall; K Höglund; C A Reynolds; N Pizzinat; M A Oyama
Journal:  J Vet Intern Med       Date:  2014-08-21       Impact factor: 3.333

3.  Serum proteomic profiles in CKCS with Mitral valve disease.

Authors:  Chiara Locatelli; Cristian Piras; Giulia Riscazzi; Isabella Alloggio; Ilaria Spalla; Alessio Soggiu; Viviana Greco; Luigi Bonizzi; Paola Roncada; Paola G Brambilla
Journal:  BMC Vet Res       Date:  2017-02-07       Impact factor: 2.741

4.  Real-Time 3-Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease.

Authors:  A Tidholm; A Bodegård-Westling; K Höglund; J Häggström; I Ljungvall
Journal:  J Vet Intern Med       Date:  2017-01-21       Impact factor: 3.333

5.  Polymorphisms in the serotonin transporter gene and circulating concentrations of neurotransmitters in Cavalier King Charles Spaniels with myxomatous mitral valve disease.

Authors:  Maria J Reimann; Merete Fredholm; Signe E Cremer; Liselotte B Christiansen; Kathryn M Meurs; Jacob E Møller; Jens Häggström; Jens Lykkesfeldt; Lisbeth H Olsen
Journal:  J Vet Intern Med       Date:  2021-10-02       Impact factor: 3.333

6.  Discrepancies in identification of left atrial enlargement using left atrial volume versus left atrial-to-aortic root ratio in dogs.

Authors:  S Wesselowski; M Borgarelli; N M Bello; J Abbott
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

7.  Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.

Authors:  H-S Kim; J-H Kang; E-B Jeung; M-P Yang
Journal:  J Vet Intern Med       Date:  2016-08-30       Impact factor: 3.333

Review 8.  Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.

Authors:  Giulio Menciotti; Michele Borgarelli
Journal:  Vet Sci       Date:  2017-09-26

9.  The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease.

Authors:  Katja Höglund; Jens Häggström; Odd Viking Höglund; Mats Stridsberg; Anna Tidholm; Ingrid Ljungvall
Journal:  Acta Vet Scand       Date:  2020-08-05       Impact factor: 1.695

10.  The genetic consequences of dog breed formation-Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels.

Authors:  Erik Axelsson; Ingrid Ljungvall; Priyasma Bhoumik; Laura Bas Conn; Eva Muren; Åsa Ohlsson; Lisbeth Høier Olsen; Karolina Engdahl; Ragnvi Hagman; Jeanette Hanson; Dmytro Kryvokhyzha; Mats Pettersson; Olivier Grenet; Jonathan Moggs; Alberto Del Rio-Espinola; Christian Epe; Bruce Taillon; Nilesh Tawari; Shrinivas Mane; Troy Hawkins; Åke Hedhammar; Philippe Gruet; Jens Häggström; Kerstin Lindblad-Toh
Journal:  PLoS Genet       Date:  2021-09-02       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.